1. ALLA AKTIER
  2. NYHETER
  3. LIDDS

LIDDS

Nyheter LIDDS Nyheter alla bolag

Nomination Committee appointed for the Annual General Meeting 2024 in LIDDS

UPPSALA, SWEDEN – LIDDS AB (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2024. The Nomination Committee shall, according to decided principles for the appointment of the Nomination Committee, consist of three representatives for the two largest shareholders.

The main task of the Nomination Committee is to submit proposals for Chairman of the Board and other members of the Board, remuneration for Board work, the election and remuneration of auditors. The Nomination Committee shall be composed of members appointed by the two largest shareholders in the company based on ownership of the company as per the end of September 2023.

Accordingly, the following committee members have been appointed:
• Bengt Viterius, Chairman
• Niklas Folkesson
• Daniel Lifveredson

The Nomination Committee’s proposals will be presented in the Notice to the AGM 2024 and on the company web site, www.liddspharma.com. Shareholders desiring to submit comments or proposals to the nomination committee can send them via e-mail to info@liddspharma.com.

For additional information, please contact

Jenni Björnulfson, CEO and CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

Nomination Committee appointed for the Annual General Meeting 2024 in LIDDS

Datum 2023-12-04, kl 16:25
Källa MFN
Bifogade filer
Nomination Committee appointed for the Annual General Meeting 2024 in LIDDS
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!